📣New eBook: Explore the emerging trends shaping next-gen ADC development: Next-Generation Antibody Drug Conjugates

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimization Campaign - CCS1477

    CellCentric Lead Optimization Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Blog
How FIDA Enhances Protein Projects at Sygnature Discovery
Revolutionizing our Protein Science: How FIDA Enhances Protein Projects at Sygnature Written by …
Blog
Channelrhodopsin: A protein tool being used to help our brain understand itself
We in the Protein Science & Structural Biology department are passionate about proteins, and membrane…
Case Studies
Advancing Pain Research with Naᵥ1.7 and Naᵥ1.8 Electrophysiology
Chronic pain remains a major unmet need in drug discovery. Although current therapies can…
Case Studies
Using 𝑋𝑒𝑛𝑜𝑝𝑢𝑠 Oocyte TEVC to Generate Functional Insights for Challenging Membrane Proteins
Many of today’s therapeutic targets sit within the cell membrane. Ion channels, transporters and…
Blog
Ion Channel Targets in Pain Discovery: Lessons from TRPM2
Emerging biology highlights why functional validation matters Chronic pain remains one of the most…
Case Studies
Rethinking E. coli Expression: How ClearColi™ is Simplifying Cost Effective, Low-Endotoxin Protein Production at Sygnature Discovery
The challenge of endotoxin contamination is one of the most persistent hurdles in recombinant protein…
Blog
Horseshoe Crabs and Endotoxins
With over 4 billion people to date (March 2022) having received…
Blog
Insights From World ADC 2026 – Beyond the Payload: What Will Define the Next Generation of ADCs?
At World ADC San Diego 2026, ADC leaders from Pfizer, AstraZeneca, Callio Therapeutics, Iksuda…
Blog
Understanding Target Biology
Understanding target biology is critical to making informed decisions throughout drug discovery. By combining pathway analysis, omics data, and target-class expertise, researchers can build a clearer picture of disease mechanisms, identify the most effective intervention strategies, and reduce scientific risk before significant resources are committed.
Case Studies
Overcoming Complex Cytotoxic Chemistry: Discovery to Clinic in 14 Months
Advancing AVA6103 from discovery to clinical candidate nomination in just 14 months

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch